Nine companies entered the public market this week, led by customer experience software provider Medallia (MDLA) with a first day pop of 76%. The software company priced at $21, well above the range, to raise $326 million at a fully...read more
Genmab, which is developing novel antibodies for cancer and other diseases, raised $506 million in its US IPO by offering 28.5 million ADSs at $17.75, slightly below the as-converted last close of its shares on the Nasdaq Copenhagen and at the time of its launch...read more
July's post-holiday flood of IPOs is upon us, with nine diverse offerings and a direct listing scheduled for the second-most active week of the year. The three largest IPOs come from Asia, Europe, and South America, but based on the strong reception of recent...read more
Genmab, which is developing novel antibodies for cancer and other diseases, announced terms for its IPO on Tuesday. The Copenhagen, Denmark-based company plans to raise $503 million by offering 27.8 million ADSs at a price of $18.11, the as-converted...read more
US IPO Weekly Recap: Medallia tops a 9-IPO week with a 76% first day return
Nine companies entered the public market this week, led by customer experience software provider Medallia (MDLA) with a first day pop of 76%. The software company priced at $21, well above the range, to raise $326 million at a fully...read more
Cancer biotech Genmab prices US IPO at $17.75
Genmab, which is developing novel antibodies for cancer and other diseases, raised $506 million in its US IPO by offering 28.5 million ADSs at $17.75, slightly below the as-converted last close of its shares on the Nasdaq Copenhagen and at the time of its launch...read more
US IPO Week Ahead: Large foreign filers and a US unicorn lead 10-deal week
July's post-holiday flood of IPOs is upon us, with nine diverse offerings and a direct listing scheduled for the second-most active week of the year. The three largest IPOs come from Asia, Europe, and South America, but based on the strong reception of recent...read more
Anitbody biotech Genmab sets terms for $503 million US IPO
Genmab, which is developing novel antibodies for cancer and other diseases, announced terms for its IPO on Tuesday. The Copenhagen, Denmark-based company plans to raise $503 million by offering 27.8 million ADSs at a price of $18.11, the as-converted...read more